

# A clinical approach to managing obesity in adults

XI MAY ZHEN MB BS, FRACP

SAMANTHA L. HOCKING MB BS, MMed(Clin Epi), FRACP, PhD

*Obesity is a complex chronic disease that is strongly associated with an increased risk of all-cause mortality. Therapies for optimising weight and metabolic health should be guided by an individual's body mass index (with consideration of body composition), comorbidities, and the presence and severity of obesity-associated complications.*

## What are the health risks from obesity?

Obesity is a complex chronic disease that is strongly associated with an increased risk of all-cause mortality as well as cardiovascular and cancer mortality.<sup>1-3</sup> Importantly, the longer the duration of obesity, the greater its impact on mortality, which is an important consideration in young adults with obesity.<sup>4</sup>

Excess weight is directly linked to various cardiovascular risk factors.<sup>5</sup> Obesity is associated with an increased risk of various diseases including type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), chronic kidney disease and metabolic-associated fatty liver disease.<sup>6</sup> The physical burden of carrying excess body weight results in mechanical complications including obstructive sleep apnoea (OSA), urinary incontinence, osteoarthritis and low back pain.<sup>6-8</sup> Obesity is also a state of chronic low-grade inflammation and a major risk factor for at least 13 different types of cancer (Box 1) and dementia.<sup>9,10</sup>

**MedicineToday** FOCUS ON OBESITY 2025; 26(8 Suppl): 9-15

First published in *Endocrinology Today* 2023; 12(1): 15-21

Updated August 2025

Dr Zhen is a Staff Specialist and Clinical Lead of the Blacktown Hospital Metabolic Program; Conjoint Senior Lecturer with the School of Medicine, Western Sydney University, Sydney; and an Honorary Visiting Medical Officer at the Department of Endocrinology, Royal Prince Alfred Hospital, Sydney. Associate Professor Hocking is an Endocrinologist at the Department of Endocrinology, Royal Prince Alfred Hospital, Sydney; President of the National Association of Clinical Obesity Services, Sydney; a Member of Council for the Australian New Zealand Obesity Society, Sydney; and a Clinical Academic at the Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW.



## Key Points

- **Obesity is a complex chronic disease associated with increased morbidity and mortality.**
- **Routine screening is required to assess the complications of obesity.**
- **Preconception counselling is crucial as many women are unaware of the potential adverse effects of obesity on both maternal and offspring outcomes.**
- **Even small reductions in body weight can reduce the complications of obesity.**
- **For many individuals, lifestyle interventions alone will not achieve the required amount of weight loss, and pharmacotherapy with or without metabolic surgery should be considered.**

In women of reproductive age, obesity is associated with menstrual disturbance, impairment of oocyte development and quality, anovulation, delayed conception, as well as worsening of the clinical features of polycystic ovary syndrome (PCOS).<sup>11,12</sup> Depression appears to be more common amongst people with obesity compared to those of a healthy weight, although the direction of causality is not clear.<sup>13,14</sup> Women tend to experience more mental health complications associated with obesity than men, which can be exacerbated by discrimination against individuals with a higher body mass index (BMI).<sup>15,16</sup> This can lead to a strong dissatisfaction with one's body weight, shape, or both, which is a risk factor for the development of comorbid disordered eating behaviours.<sup>17,18</sup> The psychological impact of weight stigmatisation can perpetuate weight gain and lead to the development of other chronic diseases.<sup>19</sup>

## Why is weight loss important?

Even modest weight loss significantly reduces the complications of obesity. A 5% reduction in total body weight can prevent the development of T2DM in individuals with prediabetes, improve glycaemic control in individuals with T2DM, reduce liver fat, lower systolic blood pressure and triglyceride levels, and improve physical disability amongst patients with knee osteoarthritis.<sup>20-25</sup> Greater weight loss

**1. Cancers associated with overweight and obesity**

- |                              |                    |                           |
|------------------------------|--------------------|---------------------------|
| • Endometrial                | • Kidney           | • Gallbladder             |
| • Oesophageal adenocarcinoma | • Multiple myeloma | • Breast (postmenopausal) |
| • Gastric cardia             | • Meningioma       | • Ovarian                 |
| • Liver                      | • Pancreatic       | • Thyroid                 |
|                              | • Colon and rectal |                           |

(≥10%) results in additional health benefits including remission of T2DM, improvements in OSA, reductions in liver inflammation and injury, and a lower risk of cardiovascular events and mortality.<sup>26-30</sup> In women with PCOS, lifestyle interventions improve hyperandrogenism even if weight loss is minimal, although greater weight loss from metabolic surgery also results in improved menstrual regularity and can result in remission.<sup>12,31</sup>

In women with obesity and subfertility, lifestyle interventions have a positive effect on pregnancy and natural conception rates, although the effect on live birth rates remains uncertain.<sup>32</sup> Concerns about the presence of concomitant disordered eating behaviours may caution clinicians against recommending weight management. However, weight management approaches (including medically supervised moderate and severe caloric restriction in combination with behavioural weight loss therapy) do not induce binge eating in overweight adults without pretreatment binge eating, and can reduce binge eating in those with pretreatment binge eating behaviours.<sup>33,34</sup>

**When and how do you screen for secondary causes of obesity?**

Obesity is a chronic and complex disease influenced by many factors including a genetic predisposition to obesity, work and social environments that promote the consumption of convenient highly processed foods and sedentary behaviour, metabolic adaptations defending against weight loss, as well as other psychosocial and economic drivers.<sup>35</sup> For most individuals, their risk for obesity will be conferred by numerous variants in a number of genetic drivers, that is, polygenic obesity. However, screening for rarer monogenic subtypes of obesity should be considered if extreme obesity occurs at a young age (<5 years of age), particularly when accompanied by clinical features of genetic obesity syndromes (such as extreme hyperphagia), a family history of extreme obesity, or both.<sup>36</sup>

A relatively sudden increase in weight may suggest an endocrine cause for obesity, and screening for causes such as hypothyroidism and Cushing’s syndrome (including iatrogenic cortisol excess from exogenous glucocorticoids) should be considered, particularly if suggestive clinical features are present. For instance, if the patient reports dry skin, cold intolerance or other features to suggest hypothyroidism, check the thyroid stimulating hormone level. If there are clinical features of Cushing’s syndrome (e.g. easy bruising, facial plethora, proximal myopathy or wide purple striae), measure the midnight salivary cortisol, 24-hour urinary free cortisol, or arrange a 1 mg overnight dexamethasone suppression test (the

diagnostic approach will depend on the pretest probability). PCOS should be considered if there are clinical features of insulin resistance (acanthosis nigricans), hyperandrogenism (acne and hirsutism), or oligo-ovulation or anovulation (irregular menstrual cycles).

Review the use of medications associated with weight gain such as antidepressants (e.g. mirtazapine, amitriptyline, sertraline, fluoxetine, paroxetine), antipsychotics (e.g. olanzapine, clozapine, quetiapine, risperidone), anticonvulsants (e.g. valproate, carbamazepine, gabapentin) and treatments for diabetes (e.g. insulin, sulphonylureas, thiazolidinediones), and consider switching to less obesogenic medications if possible.<sup>37</sup> If there is diagnostic uncertainty, consider referral to a specialist service.

**How do you assess for obesity-associated complications?**

The following routine assessments should be performed in all adults with overweight and obesity:<sup>38</sup>

- weight, height and BMI
- waist circumference
- blood pressure measurement (using an appropriately sized arm cuff)
- assessment of fasting glucose levels (repeated regularly according to local guidelines)<sup>39</sup>
- fasting lipid profile
- liver function tests and screening tools such as calculation of the FIB-4 score (<https://liver.org.au/health-professionals/fib-4-calculator/>)
- screening for OSA (e.g. STOP-BANG questionnaire)
- screening for depression and anxiety (e.g. K10 screening tool or Patient Health Questionnaire [PHQ]-9)
- screening for disordered eating (e.g. Eating Disorder Examination Questionnaire [EDE-Q])
- screening for CVD (e.g. [www.cvdcheck.org.au](http://www.cvdcheck.org.au)) for all adults aged 45 years and older (or 30 years and older for Aboriginal and Torres Strait Islander people) without existing CVD or not already known to be at increased risk of CVD
- age-appropriate cancer screening (e.g. bowel, breast, cervix and prostate)
- in women, screening for clinical signs of hyperandrogenism (e.g. hirsutism, acne, male pattern balding).

**How do you identify candidates for weight loss interventions?**

Treatments for obesity should be guided by an individual’s BMI and waist circumference, and the presence and severity of obesity-associated complications. It is imperative that lifestyle modifications are included in the treatment pathway with goals focused on reducing energy intake, optimising diet quality and increasing energy expenditure. Antiobesity pharmacotherapies are indicated for any individual with a BMI of 30kg/m<sup>2</sup> or more, or a BMI of 27kg/m<sup>2</sup> or more plus the presence of at least one weight-associated comorbidity (see the case study in Box 2). Consider commencing

## 2. A young woman with post-traumatic stress disorder and rapid weight gain

### Case scenario

A 32-year-old woman presents to her GP because of concerns about her recent rapid weight gain. She reports a weight gain of 15 kg over the past 12 months and has now reached a weight of 98 kg (body mass index 36 kg/m<sup>2</sup>). She is frustrated about her inability to control her eating, dislikes how she looks and feels her self-esteem and mood are worsening. This has led to a vicious cycle of comfort eating followed by further weight gain. She admits that she has a 'sweet tooth' and particularly craves chocolate.

She was diagnosed with polycystic ovary syndrome 12 years ago, on the basis of irregular menses and clinical features consistent with hyperandrogenism. She was found to be insulin resistant and was started on metformin 500mg twice daily. In an attempt to reduce her weight, she tried low carbohydrate, intermittent fasting and 'keto' diets with some success and managed to lose about 5 to 7 kg on each diet. However, each weight loss attempt was followed by weight regain, leading to a gradual increase in her body weight overall.

One year ago, she was diagnosed with post-traumatic stress disorder (PTSD) after experiencing years of bullying at work. She was started on sertraline 100 mg daily and has been regularly seeing a psychologist. Since starting sertraline, her weight has increased rapidly despite engaging with a dietitian and exercise physiologist using a chronic disease management plan. She is keen to explore additional therapies to assist with weight loss.

### Treatment strategies

Weight optimisation in this case requires a sensitive approach to avoid provoking feelings of weight stigma or bias. This woman has reported frustration at an inability to control her eating, a vicious cycle of 'comfort' eating, followed by further weight gain, poor body image and worsening self-esteem and mood. She has also already engaged in attempts to reduce her weight. If she was to continue unsupervised food restriction or food elimination, this could not only leave her vulnerable to the development of disordered eating but could actively jeopardise her ability to develop

lifestyle modifications that support healthy weight regulation and the reduction of eating as a means of emotion regulation.

A detailed review of her dietary and exercise patterns is crucial. The ongoing rapid weight gain suggests that there is suboptimal adherence to lifestyle recommendations, and the reasons underlying this need to be explored so that appropriate interventions can be initiated and support provided. In addition to her diagnosis of PTSD, she may also be vulnerable to the development of disordered eating behaviours and a mood disorder. She requires a multidisciplinary approach to weight management including medical, dietetic and psychological input to facilitate supervised weight loss and the development of healthy lifestyle and eating behaviours. A mental health treatment plan with referral to a psychologist is required to address weight loss expectations and body image dissatisfaction, with body acceptance necessary to reduce the likelihood of behaviours that may perpetuate disordered eating (particularly if her weight stabilises higher than expected). Nonpharmacological treatment for her PTSD could also be explored.

The use of sertraline should be reviewed with referral to psychiatry, if needed. Weight loss pharmacotherapy is likely required in this situation to help suppress her appetite and food cravings, and to promote sustained weight loss. In this clinical scenario, a glucagon-like peptide 1 (GLP-1) receptor agonist or dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist would be the most appropriate pharmacotherapy given her insulin resistance and mood disorder. It would be prudent for clinicians to monitor patients for any mood changes during treatment with these agents. Her current use of a selective serotonin reuptake inhibitor is a precaution to the use of phentermine and naltrexone/bupropion, as the use of these agents may have an adverse effect on her mood. Pharmacotherapy should be prescribed in addition to ongoing dietetic support to achieve a balanced and nutritionally complete reduced energy diet and regular physical activity.

antiobesity pharmacotherapies when lifestyle modifications alone have been unsuccessful in achieving desired weight loss, or to maintain weight loss and prevent weight regain. Metabolic surgery should be considered for adults with a BMI of 40kg/m<sup>2</sup> or more, or a BMI of 30.0 to 39.9kg/m<sup>2</sup> with comorbidities that may improve with weight loss.

### Special considerations in women of childbearing age

Many women planning to conceive are unaware of the potential adverse effects of obesity on both maternal and offspring outcomes. Obesity is associated with reduced fertility and oocyte quality, and also adversely impacts the quality and early development of the embryo.<sup>40,41</sup> Obesity is associated with increased risks in the antenatal, intrapartum and postpartum periods, as well as increased anaesthetic risk.<sup>42</sup> There is a direct relationship between the class of obesity and the likelihood of serious adverse outcomes.<sup>42</sup> A large retrospective cohort study found that when compared with normal-weight women, the hazard ratio for stillbirth was 1.36 for overweight women, 1.71 for women with class I obesity, 2.00 for women with class II obesity, 2.48 for women with

class III obesity and 3.16 for women with a BMI of 50kg/m<sup>2</sup> and above.<sup>43</sup> Perinatal exposure to maternal obesity is also associated with cardiometabolic morbidity in the offspring.<sup>44,45</sup>

Height, weight and BMI should be measured at preconception appointments. The risks of overweight and obesity on fertility and pregnancy outcomes need to be discussed using a sensitive and person-centred approach. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists *Management of Obesity in Pregnancy Best Practice Statement* recommends starting folic acid 5mg daily (due to the increased risk of neural tube defects) and iodine 150mcg daily (unless contraindicated) in the preconception period for women with obesity.<sup>46</sup>

Ideally, weight and metabolic health should be optimised prior to conception to reduce the risk of pregnancy-associated complications and to minimise exposure of the foetus to an adverse metabolic environment. A multifaceted and holistic approach to weight management is best provided by an experienced healthcare team. At present, there is a lack of conclusive randomised trial data regarding the optimal weight loss interventions for pre-pregnancy use.<sup>46</sup>

**Table. Summary of medications with TGA approval for weight loss<sup>52,54,62-72</sup>**

	<b>Phentermine (Alenami, Duromine, Metermine, Phentodur, Supremine)</b>	<b>Naltrexone/bupropion (Contrave)</b>	<b>Orlistat (Xenical)</b>	<b>Liraglutide (Saxenda) and semaglutide (Wegovy)*</b>	<b>Tirzepatide (Mounjaro)*</b>
Formulation	Oral tablet			Subcutaneous injection	
Mechanism of action	Sympathomimetic action resulting in decreased food intake and increased resting energy expenditure	Potentially modulates food cravings and mood via hypothalamic melanocortin system as well as brain reward systems <sup>62,63</sup>	Inhibits pancreatic and gastric lipase, resulting in reduced fat absorption	GLP-1 RAs (liraglutide and semaglutide) and GIP/GLP-1 RAs (tirzepatide) increase glucose-dependent insulin secretion, decrease inappropriate glucagon secretion, slow gastric emptying and regulate food-associated behaviours, resulting in decreased appetite as well as increased postprandial satiety and fullness.  The dual agonism of tirzepatide, at GIP and GLP-1 receptors, provides additional mechanisms of action which are likely more effective at countering the complex pathways involved in achieving and maintaining weight loss. <sup>64,65</sup> GIP and GLP-1 have both overlapping and nonoverlapping expression and function. <sup>66-68</sup>  Furthermore, adipocytes lack functional GLP-1 receptors but have functional GIP receptors that may play a role in the direct regulation of adipocytes by tirzepatide <sup>69,70</sup>	
Special warnings and precautions for use	<ul style="list-style-type: none"> <li>• Uncontrolled hypertension</li> <li>• Cardiac disease</li> <li>• Hyperthyroidism</li> <li>• Glaucoma</li> <li>• Pregnancy</li> <li>• Breastfeeding</li> <li>• Previous drug abuse</li> <li>• Use of MAOIs, SSRIs</li> </ul>	<ul style="list-style-type: none"> <li>• Uncontrolled hypertension</li> <li>• History of seizures</li> <li>• Known central nervous system tumours</li> <li>• Chronic opioid or opiate agonist/partial agonist use, or acute opiate withdrawal</li> <li>• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs</li> <li>• Anorexia nervosa or bulimia</li> <li>• Pregnancy</li> <li>• Breastfeeding</li> <li>• Severe hepatic or renal impairment</li> <li>• Use within 14 days of treatment with MAOIs</li> </ul>	<ul style="list-style-type: none"> <li>• Anorexia</li> <li>• Fat-soluble vitamin deficiency</li> <li>• Malabsorption</li> <li>• Cholestasis</li> <li>• Pregnancy</li> <li>• Breastfeeding</li> <li>• Patients with or at risk of oxalate nephropathy</li> </ul>	<ul style="list-style-type: none"> <li>• Pregnancy</li> <li>• Breastfeeding</li> <li>• History of pancreatitis (particularly when the inciting cause has not been removed)</li> <li>• Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B</li> </ul>	
Abbreviations: GLP-1 RA = glucagon-like peptide 1 receptor agonist; GIP/GLP-1 RA = dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist; GLP-1 = glucagon-like peptide 1; GIP = glucose-dependent insulinotropic polypeptide; MAOI = monoamine oxidase inhibitor; SSRI = selective serotonin reuptake inhibitor; T2DM = type 2 diabetes mellitus. * Semaglutide 1mg (Ozempic) is TGA approved for type 2 diabetes; semaglutide 2.4mg (Wegovy) is TGA approved for chronic weight management and to reduce the risk of major adverse CV events in people with established CV disease and a BMI of $\geq 27$ kg/m <sup>2</sup> without established type 1 or type 2 diabetes; tirzepatide (Mounjaro) is TGA approved for type 2 diabetes, chronic weight management and obstructive sleep apnoea in patients with obesity.					

Women should be advised to use reliable forms of contraception while working on weight loss, particularly when using antiobesity pharmacotherapy. Medications for weight loss should be avoided during the time of conception, during pregnancy and while breastfeeding for safety reasons. Usually, antiobesity pharmacotherapy should be ceased for a period of at least six weeks prior to attempting to conceive (the time period will vary depending on the agent used); the manufacturers of semaglutide have indicated that this agent

should be discontinued at least two months before a planned pregnancy due to the medication's long half-life.<sup>47</sup>

Women who have undergone metabolic surgery require additional nutritional supplementation and careful monitoring for micronutrient deficiencies in the preconception period. It is recommended that conception is avoided for 12 to 18 months following metabolic surgery, particularly when there is rapid weight loss or nutritional deficiencies.<sup>48</sup>

**Table. Summary of medications with TGA approval for weight loss<sup>52,54,62-72</sup> continued**

	<b>Phentermine (Alenami, Duromine, Metermine, Phentodur, Supremine)</b>	<b>Naltrexone/bupropion (Contrave)</b>	<b>Orlistat (Xenical)</b>	<b>Liraglutide (Saxenda) and semaglutide (Wegovy)*</b>	<b>Tirzepatide (Mounjaro)*</b>
Adverse effects	<ul style="list-style-type: none"> <li>• Hypertension</li> <li>• Tachycardia</li> <li>• Insomnia</li> <li>• Restlessness</li> <li>• Dry mouth</li> <li>• Constipation or diarrhoea</li> </ul>	<ul style="list-style-type: none"> <li>• Nausea or vomiting</li> <li>• Constipation</li> <li>• Dizziness</li> <li>• Hypertension</li> <li>• Tachycardia</li> <li>• Headaches</li> <li>• Insomnia</li> <li>• Dry mouth</li> <li>• Word finding difficulty</li> <li>• Neuropsychiatric adverse events</li> <li>• Seizures</li> <li>• Angle-closure glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy</li> </ul>	<ul style="list-style-type: none"> <li>• Steatorrhoea</li> <li>• Excessive flatus with or without discharge</li> <li>• Fat-soluble vitamin deficiency</li> <li>• Oxalate-induced acute kidney injury</li> </ul>	<ul style="list-style-type: none"> <li>• Nausea or vomiting</li> <li>• Diarrhoea</li> <li>• Constipation</li> <li>• Pancreatitis</li> <li>• Gallstones</li> <li>• Cholecystitis</li> <li>• Potential increased risk of medullary thyroid cancer</li> </ul>	
Other considerations	Approved for short-term use (12 weeks), subject to periodic medical review	Useful option for those also aiming for alcohol or smoking cessation	Orlistat markedly decreases blood cyclosporin concentrations. Warfarin doses may need to be reduced due to reduced absorption of vitamin K. Coprescribing with psyllium may reduce the gastrointestinal side effects of orlistat	<p>Saxenda, one brand of liraglutide, was discontinued by the manufacturer at the end of 2025. The TGA has approved generic liraglutide.</p> <p>Semaglutide is currently available in two forms:</p> <ul style="list-style-type: none"> <li>• Ozempic: PBS subsidised for people with T2DM meeting criteria, but not TGA approved for weight management</li> <li>• Wegovy: TGA approved for adults as an adjunct to lifestyle modification for chronic weight management and as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events</li> </ul> <p>The SELECT trial demonstrated that subcutaneous semaglutide at a dose of 2.4 mg weekly was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke at a mean follow up of 39.8 months in patients with pre-existing cardiovascular disease and overweight or obesity but without diabetes<sup>54</sup></p>	The SURMOUNT-5 trial showed that, among people with obesity (but without diabetes), treatment with tirzepatide 10 or 15 mg weekly was superior to semaglutide 1.7 or 2.4 mg weekly with regard to body weight and waist circumference reduction at week 72 <sup>64</sup>

Abbreviations: GLP-1 RA = glucagon-like peptide 1 receptor agonist; GIP/GLP-1 RA = dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist; GLP-1 = glucagon-like peptide 1; GIP = glucose-dependent insulinotropic polypeptide; MAOI = monoamine oxidase inhibitor; SSRI = selective serotonin reuptake inhibitor; T2DM = type 2 diabetes mellitus.

\* Semaglutide 1 mg (Ozempic) is TGA approved for type 2 diabetes; semaglutide 2.4 mg (Wegovy) is TGA approved for chronic weight management and to reduce the risk of major adverse CV events in people with established CV disease and a BMI of  $\geq 27 \text{ kg/m}^2$  without established type 1 or type 2 diabetes; tirzepatide (Mounjaro) is TGA approved for type 2 diabetes, chronic weight management and obstructive sleep apnoea in patients with obesity.

### Overview of lifestyle interventions and the role of behaviour therapy

Lifestyle interventions to reduce energy intake, increase energy expenditure and improve nutritional quality are the cornerstone of weight management. A network of experienced clinicians providing support and supervision is key to the success of lifestyle interventions. Please refer to the *Australian Dietary Guidelines* and the *Australian Guide to Healthy Eating* for general dietary advice.<sup>49,50</sup> Involving an experienced multidisciplinary team (including an accredited practicing dietitian and exercise physiologist) is helpful and creates a network of support around the patient. Behaviour therapy is key to helping people make long-term changes in the way they respond to stimuli that trigger eating. Behaviour modification programs offered by psychologists and other suitably experienced clinicians can result in more weight loss and less weight regain.<sup>51</sup> If there is any concern for a binge eating disorder, consider referral to a health practitioner with expertise in eating disorders.

Options for reducing energy intake include:

- Reduced Energy Diet (RED): modest energy deficit of 2000 to 4000 kJ/day (energy deficit of 480 to 960 kcal/day)
- Low Energy Diet (LED): aim to reduce total daily energy intake to 4200 to 5000 kJ (1000 to 1200 kcal/day)
- Very Low Energy Diet (VLED): aim to reduce energy intake to less than 3300 kJ/day (800 kcal/day) by substituting meals with formulated meal replacements. Medical supervision and regular clinical review are helpful when using VLEDs, as there are contraindications and precautions.

Those with a BMI of 30 to 39.9 kg/m<sup>2</sup> and no obesity-associated complications could trial RED or LED initially, and then consider VLED if weight loss is inadequate.<sup>52</sup> People with a BMI of 30 to 39.9 kg/m<sup>2</sup> and obesity-associated complications, and those with a BMI of 40 kg/m<sup>2</sup> and above should generally commence VLED directly.<sup>52</sup> Please refer to the latest *Australian Obesity Management Algorithm* for further details such as contraindications to VLED, and the use of VLED in special groups (e.g. chronic kidney disease, people with diabetes and those using sodium-glucose cotransporter-2 inhibitors or warfarin).<sup>52</sup>

Regular physical activity is a key component of weight management and exercise programs should be titrated to individual needs. For instance, people with musculoskeletal problems may benefit from choosing aquatic activities, and those with cardiovascular or respiratory diseases will likely require a gentler program as tolerated. An exercise physiologist will be able to provide tailored advice on suitable exercise programs for the patient. For general advice on physical activity, please refer to the *Physical Activity and Exercise Guidelines* produced by the Australian Government.<sup>53</sup>

### What are the pharmacotherapies available for weight loss?

At present, phentermine, naltrexone/bupropion, orlistat, liraglutide, semaglutide (2.4 mg weekly dose) and tirzepatide are approved by the

TGA for chronic weight management. Semaglutide (2.4 mg weekly dose) is also approved by the TGA as an adjunct to standard-of-care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in adults with established cardiovascular disease, with a BMI of 27 kg/m<sup>2</sup> and above, and without established type 1 or type 2 diabetes. Topiramate and phentermine-topiramate are frequently used off-label for weight management but are not currently approved by the TGA for this indication.

The choice of pharmacotherapy should be based on a careful assessment of factors such as patient age, comorbidities (e.g. diabetes as well as cardiovascular, chronic kidney or liver diseases), medication side effect profiles and patient preference. For instance, among those with pre-existing cardiovascular disease and overweight or obesity (but without diabetes), subcutaneous semaglutide 2.4 mg weekly was superior to placebo in reducing the incidence of nonfatal myocardial infarction, death from cardiovascular causes or nonfatal stroke (mean follow-up period was 39.8 months).<sup>54</sup> Semaglutide 2.4 mg once weekly has also been shown to significantly improve pain associated with knee osteoarthritis and to improve symptoms and physical limitations in individuals with obesity and heart failure with preserved ejection fraction.<sup>55,56</sup> In adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced liver fibrosis, subcutaneous semaglutide 2.4 mg weekly was shown to result in higher rates of steatohepatitis resolution and greater reduction in liver fibrosis when compared to placebo at interim analysis after 72 weeks of treatment.<sup>57</sup> Similarly, in adults with MASH and moderate or severe fibrosis, tirzepatide (5 mg, 10 mg or 15 mg) for 52 weeks was more effective than placebo in achieving resolution of MASH without worsening of fibrosis.<sup>58</sup>

Tirzepatide has been shown to reduce OSA severity when compared to placebo in adults with OSA and obesity, as well as reduce cardiovascular death and worsening heart failure in people with obesity and heart failure with preserved ejection fraction.<sup>59,60</sup>

Regular monitoring while on antiobesity pharmacotherapy is crucial to monitor progress and ensure safety. If patients are unable to lose at least 5% of total body weight after 12 to 24 weeks of treatment on the maximum dose of the chosen antiobesity agent, it is important to review medication adherence and individual circumstances, and consider whether a trial of an alternative medication is appropriate.

Certain patient groups require close monitoring on antiobesity pharmacotherapy. For instance, those with diabetes on glucose-lowering therapy (especially insulin, sulphonylureas or both) require close monitoring of blood glucose levels to avoid hypoglycaemia. Similarly, patients with hypertension require regular blood pressure monitoring with down-titration of antihypertensive therapy as appropriate.

Abrupt discontinuation of antiobesity pharmacotherapy is associated with weight regain and recurrence of weight-associated comorbidities in most cases. For instance, at one year following cessation of semaglutide 2.4 mg once weekly and lifestyle

interventions (administered for 68 weeks, including 16 weeks of semaglutide dose escalation), participants in the STEP 1 trial extension regained two-thirds of their prior weight loss. Cardiometabolic improvements observed during treatment (from week zero to week 68) also reverted towards baseline after one year of therapy withdrawal.<sup>61</sup>

A summary of all the TGA approved medications for weight loss is shown in the Table.<sup>52,54,62-72</sup>

### Overview of metabolic surgery

For individuals with obesity-associated complications, a high BMI or for those in whom lifestyle and pharmacotherapy have not resulted in the required weight loss, metabolic surgery may be considered as part of a comprehensive treatment plan. The potential benefits of metabolic surgery should be carefully weighed against the individual's risk profile, and a thorough evaluation of mental health and psychosocial factors is critical. Surgery should ideally be performed at high-volume centres with experienced multidisciplinary teams. After metabolic surgery, patients will require long-term monitoring of micronutrient and nutritional status, as well as ongoing review of lifestyle and psychological factors.

The Second Diabetes Surgery Summit, held in 2016 and endorsed by the Australian Diabetes Society, produced guidelines that state that metabolic surgery is recommended for individuals with:

- a BMI of 40 kg/m<sup>2</sup> and above, regardless of the level of glycaemic control or complexity of glucose-lowering regimens
- a BMI of 35.0 to 39.9 kg/m<sup>2</sup>, with inadequate glycaemic management despite lifestyle and optimal medical therapy.<sup>73</sup>

The American Society for Metabolic and Bariatric Surgery and International Federation for the Surgery of Obesity and Metabolic Disorders *Indications for Metabolic and Bariatric Surgery 2022* state that metabolic and bariatric surgery should be:

- recommended for individuals with a BMI of 35 kg/m<sup>2</sup> and above, regardless of presence, absence or severity of comorbidities
- considered for individuals with metabolic disease and a BMI of 30 to 34.9 kg/m<sup>2</sup>

- offered to individuals in the Asian population with a BMI of 27.5 kg/m<sup>2</sup> and above, noting that a BMI of 25 kg/m<sup>2</sup> and above in this group suggests clinical obesity.<sup>74</sup>

*The American Diabetes Association Standards of Medical Care in Diabetes (2025)* recommend that metabolic surgery be considered as a weight and glycaemic management option in people with diabetes with a BMI of 30.0 kg/m<sup>2</sup> and above (or  $\geq 27.5$  kg/m<sup>2</sup> in Asian American individuals) who are otherwise good surgical candidates.<sup>75</sup>

Ethnicities such as South Asian, East Asian, Southeast Asian and Australian Aboriginal and Torres Strait Islanders have been shown to have higher adiposity and diabetes risk at a given BMI.<sup>52,76-79</sup> The *Australian Obesity Management Algorithm* (updated July 2024) reflects this by adopting lower BMI thresholds for these populations: a BMI of 27.5 to 37.4 kg/m<sup>2</sup> is equivalent to a BMI of 30 to 39.9 kg/m<sup>2</sup>, and a BMI of 37.5 kg/m<sup>2</sup> and above is equivalent to a BMI of 40 kg/m<sup>2</sup> and above.<sup>52</sup>

### Summary

Therapies for managing obesity should be guided by an individual's BMI (with consideration of body composition), comorbidities and the presence and severity of obesity-associated complications. A network of experienced clinicians providing support and supervision is crucial to the success of lifestyle interventions. Lifestyle modification, pharmacotherapy and metabolic surgery should be considered as part of a comprehensive treatment plan. **ET**

---

COMPETING INTERESTS: Dr Zhen: None. Associate Professor Hocking has received honoraria for lectures and manuscript writing from Lilly Australia, AstraZeneca, Amgen, Sanofi-Aventis, Nestlé Health Sciences, iNova and Servier; support for attending meetings from Lilly Australia, Novo Nordisk, Amgen and CSL Seqirus; participation on Advisory Boards from Lilly Australia, Novo Nordisk, Ethicon and AstraZeneca; is an investigator on pharmaceutical trials of semaglutide and CagriSema (NovoNordisk), tirzepatide and retatrutide (Lilly), BI 456906 (Boehringer Ingelheim) and maridebart/cafraglutide (Amgen); and is President of the National Association of Clinical Obesity Services.

# A clinical approach to managing obesity in adults

XI MAY ZHEN MB BS, FRACP

SAMANTHA L. HOCKING MB BS, MMed(Clin Epi), FRACP, PhD

## References

1. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju Sh N, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet* 2016; 388: 776-786.
2. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet* 2009; 373: 1083-1096.
3. Chen Y, Copeland WK, Vedanthan R, et al. Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. *BMJ (Clinical research ed)* 2013; 347: f5446.
4. Abdullah A, Wolfe R, Stoelwinder JU, et al. The number of years lived with obesity and the risk of all-cause and cause-specific mortality. *Int J Epidemiol* 2011; 40: 985-996.
5. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation* 2021; 143: e984-e1010.
6. Kopelman PG. Obesity as a medical problem. *Nature* 2000; 404: 635-643.
7. Doumouchtsis SK, Loganathan J, Pergialiotis V. The role of obesity on urinary incontinence and anal incontinence in women: a review. *BJOG* 2022; 129: 162-170.
8. Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review. *Obes Rev* 2014; 15: 578-586.
9. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer-viewpoint of the IARC Working Group. *N Engl J Med* 2016; 375: 794-798.
10. Alford S, Patel D, Perakakis N, Mantzoros CS. Obesity as a risk factor for Alzheimer's disease: weighing the evidence. *Obes Rev* 2018; 19: 269-280.
11. Best D, Avenell A, Bhattacharya S. How effective are weight-loss interventions for improving fertility in women and men who are overweight or obese? A systematic review and meta-analysis of the evidence. *Hum Reprod Update* 2017; 23: 681-705.
12. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. *Cochrane Database Syst Rev* 2019; 3: CD007506.
13. Pi-Sunyer X. The medical risks of obesity. *Postgrad Med* 2009; 121: 21-33.
14. Fulton S, Décarie-Spain L, Fioramonti X, Guiard B, Nakajima S. The menace of obesity to depression and anxiety prevalence. *TEM* 2022; 33: 18-35.
15. Carpenter KM, Hasin DS, Allison DB, Faith MS. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. *Am J Public Health* 2000; 90: 251-257.
16. Blasco BV, García-Jiménez J, Bodoano I, Gutiérrez-Rojas L. Obesity and depression: its prevalence and influence as a prognostic factor: a systematic review. *Psychiatry Investig* 2020; 17: 715-724.
17. Tronieri JS, Wurst CM, Pearl RL, Allison KC. Sex differences in obesity and mental health. *Curr Psychiatry Rep* 2017; 19: 29.
18. Camacho-Barcia L, Giel KE, Jiménez-Murcia S, et al. Eating disorders and obesity: bridging clinical, neurobiological, and therapeutic perspectives. *Trends Mol Med* 2024; 30: 361-379.
19. Tomiyama AJ, Carr D, Granberg EM, et al. How and why weight stigma drives the obesity 'epidemic' and harms health. *BMC Med* 2018; 16: 123.
20. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002; 346: 393-403.
21. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001; 344: 1343-1350.
22. Look ARG, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 2013; 369: 145-154.
23. Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. *Diabetes Care* 2010; 33: 2156-2163.
24. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care* 2011; 34: 1481-1486.
25. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. *Ann Rheum Dis* 2007; 66: 433-439.
26. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open-label, cluster-randomised trial. *Lancet* 2018; 391: 541-551.
27. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. *N Engl J Med* 2017; 376: 641-651.
28. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010; 51: 121-129.
29. Look ARG, Gregg EW, Jakicic JM, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol* 2016; 4: 913-921.
30. Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. *Arch Intern Med* 2009; 169: 1619-1626.
31. Skubleny D, Switzer NJ, Gill RS, et al. The impact of bariatric surgery on polycystic ovary syndrome: a systematic review and meta-analysis. *Obes Surg* 2016; 26: 169-176.
32. Kim SY, Park ES, Kim HW. Effectiveness of non-pharmacological interventions for overweight or obese infertile women: a systematic review and meta-analysis. *Int J Environ Res Public Health* 2020; 17: 7438.
33. da Luz FQ, Hay P, Gibson AA, et al. Does severe dietary energy restriction increase binge eating in overweight or obese individuals? A systematic review. *Obes Rev* 2015; 16: 652-665.
34. Yanovski SZ. Eating disorders, race, and mythology. *Arch Fam Med* 2000; 9: 88.
35. Hruby A, Hu FB. The epidemiology of obesity: a big picture. *Pharmacoeconomics* 2015; 33: 673-689.
36. Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2017; 102: 709-757.
37. van der Valk ES, van den Akker ELT, Savas M, et al. A comprehensive diagnostic approach to detect underlying causes of obesity in adults. *Obes Rev* 2019; 20: 795-804.
38. Bessell E, Markovic TP, Fuller NR. How to provide a structured clinical assessment of a patient with overweight or obesity. *Diabetes Obes Metab* 2021; 23 (Suppl 1): 36-49.

39. Bell K, Shaw JE, Maple-Brown L, et al. A position statement on screening and management of prediabetes in adults in primary care in Australia. *Diabetes Res Clin Pract* 2020; 164: 108188.
40. Snider AP, Wood JR. Obesity induces ovarian inflammation and reduces oocyte quality. *Reproduction* 2019; 158: R79-R90.
41. Purcell SH, Moley KH. The impact of obesity on egg quality. *J Assist Reprod Genet* 2011; 28: 517-524.
42. Johansson S, Villamor E, Altman M, Bonamy AK, Granath F, Cnattingius S. Maternal overweight and obesity in early pregnancy and risk of infant mortality: a population based cohort study in Sweden. *BMJ* 2014; 349: g6572.
43. Yao R, Ananth CV, Park BY, Pereira L, Plante LA. Obesity and the risk of stillbirth: a population-based cohort study. *Am J Obstet Gynecol* 2014; 210: 457.e1-9.
44. Razaz N, Villamor E, Muraca GM, Bonamy AE, Cnattingius S. Maternal obesity and risk of cardiovascular diseases in offspring: a population-based cohort and sibling-controlled study. *Lancet Diabetes Endocrinol* 2020; 8: 572-581.
45. Kislal S, Shook LL, Edlow AG. Perinatal exposure to maternal obesity: lasting cardiometabolic impact on offspring. *Prenat Diagn* 2020; 40: 1109-1125.
46. Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Management of Obesity in Pregnancy Best Practice Statement. Melbourne: RANZCOG; 2022. Available online at: <https://ranzcof.org.au/wp-content/uploads/Management-Obesity-Pregnancy.pdf> (accessed July 2025)
47. Therapeutic Goods Administration (TGA), Ozempic Australian Product Information VV-LAB-098360. Canberra: TGA; 2025. Available online at: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2019-PI-01881-1> (accessed July 2025).
48. Busetto L, Dicker D, Azran C, et al. Obesity Management Task Force of the European Association for the Study of Obesity released "Practical Recommendations for the Post-Bariatric Surgery Medical Management". *Obes Surg* 2018; 28: 2117-2121.
49. National Health and Medical Research Council (NHMRC). Australian Dietary Guidelines. Canberra: NHMRC; 2013.
50. National Health and Medical Research Council (NHMRC). Australian Guide to Healthy Eating. Canberra: NHMRC; 2013. Available online at: <http://www.eatforhealth.gov.au/guidelines/australian-guide-healthy-eating> (accessed July 2025).
51. LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O'Connor EA. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. *Jama* 2018; 320: 1172-1191.
52. Markovic TP, Proietto J, Dixon JB, et al. The Australian Obesity Management Algorithm: A Simple Tool to Guide the Management of Obesity in Primary Care. Sydney: Australian Diabetes Society; 2024. Available online at: <https://www.diabetessociety.com.au/wp-content/uploads/2024/07/Australian-Obesity-Management-Algorithm-July-2024.pdf> (accessed July 2025).
53. Australian Government. Physical Activity and Exercise Guidelines for Adults (18 to 64 years). Canberra: Australian Government; 2021. Available online at: <https://www.health.gov.au/health-topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians/for-adults-18-to-64-years> (accessed July 2025).
54. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med* 2023; 389: 2221-2232.
55. Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. *N Engl J Med* 2024; 391: 1573-1583.
56. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2023; 389: 1069-1084.
57. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. *N Engl J Med* 2025; 392: 2089-2099.
58. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. *N Engl J Med* 2024; 391: 299-310.
59. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2025; 392: 427-437.
60. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. *N Engl J Med* 2024; 391: 1193-1205.
61. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metab* 2022; 24: 1553-1564.
62. Billes SK, Sinnayath P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. *Pharmacol Res* 2014; 84: 1-11.
63. Billes SK, Greenway FL. Combination therapy with naltrexone and bupropion for obesity. *Expert Opin Pharmacother* 2011; 12: 1813-1826.
64. Aronne LJ, Horn DB, Roux CWL, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. *N Engl J Med*. Epub ahead of print. Doi: 10.1056/NEJMoa2416394.
65. Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. *Cell Metab* 2021; 33: 833-44.e5.
66. Samms RJ, Christe ME, Collins KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. *J Clin Invest* 2021; 131: e146353.
67. Adriaenssens AE, Biggs EK, Darwish T, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. *Cell Metab* 2019; 30: 987-96.e6.
68. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. *J Diabetes Investig* 2010; 1: 8-23.
69. Regmi A, Aihara E, Christe ME, et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. *Cell Metab* 2024; 36: 1534-49.e7.
70. Kagdi S, Lyons SA, Beaudry JL. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. *J Endocrinol* 2024; 261: e230361.
71. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. *Nat Rev Drug Discov* 2022; 21: 201-223.
72. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. *Endocr Pract* 2016; 22 (Suppl 3): 1-203.
73. Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. *Diabetes Care* 2016; 39: 861-877.
74. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. *Obes Surg* 2023; 33: 3-14.
75. American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes—2025. *Diabetes Care* 2024; 48: S167-S80.
76. Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. *Lancet Diabetes Endocrinol* 2021; 9: 419-426.
77. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. *Int J Obes Relat Metab Disord* 1998; 22: 1164-1171.
78. Razak F, Anand SS, Shannon H, et al. Defining obesity cut points in a multiethnic population. *Circulation* 2007; 115: 2111-2118.
79. Hsu WC, Araneta MR, Kanaya AM, Chiang JL, Fujimoto W. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. *Diabetes Care* 2015; 38: 150-158.